NCT00712777

Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Medical University of Vienna · Academic / Other
• Sex: Male
• Age: 19 Years – 35 Years
• Healthy volunteers: Accepted

Summary

Topical brimonidine is a recently introduced alpha 2 receptor agonist which is used in the therapy of intraocular pressure (IOP) reduction in patients with open angle glaucoma. Although adequate IOP reduction is achieved in many patients there is a considerable degree of variability in IOP reduction among subjects. The reason for this interindividual variability is not entirely clear. Obviously differences in pharmacokinetic properties due to variable penetration of the drug through the cornea may be responsible. Alternatively, polymorphisms of the alpha-2 receptor may account for the differences in IOP-lowering efficacy of topical brimonidine. This hypothesis is tested in the present study. Polymorphisms of the alpha-2 receptor have been described in a number of previous studies. In addition, polymorphisms in the alpha-2 receptor gene have been shown to be functionally important, particularly a polymorphism of the alpha-2B receptor, which has a high allele frequency in caucasians.

Conditions

• Ocular Physiology
• Intraocular Pressure

Interventions

Type	Name	Description
DRUG	Brimonidine 0.2 %	Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye

Timeline

• Start date: 2008-03-01
• Primary completion: 2014-11-01
• Completion: 2014-11-01
• First posted: 2008-07-10
• Last updated: 2014-11-21

Locations

1 site across 1 country: Austria